Atossa Therapeutics Inc (ATOS) 20 Days SMA touches -0.47%: The odds favor the bear

Atossa Therapeutics Inc (NASDAQ: ATOS) on Monday, soared 11.54% from the previous trading day, before settling in for the closing price of $0.78. Within the past 52 weeks, ATOS’s price has moved between $0.55 and $1.66.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The company achieved an average annual earnings per share of -21.67%. With a float of $129.12 million, this company’s outstanding shares have now reached $129.17 million.

Let’s determine the extent of company efficiency that accounts for 15 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.

Atossa Therapeutics Inc (ATOS) Insider Activity

Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Atossa Therapeutics Inc is 0.04%, while institutional ownership is 26.47%. The most recent insider transaction that took place on May 21 ’25, was worth 9,887. In this transaction President & CEO of this company bought 11,239 shares at a rate of $0.88, taking the stock ownership to the 13,898 shares. Before that another transaction happened on Mar 26 ’25, when Company’s Director bought 10,000 for $0.70, making the entire transaction worth $7,000. This insider now owns 10,257 shares in total.

Atossa Therapeutics Inc (ATOS) Earnings and Forecasts

According to the Wall Street analysts, stocks earnings will be around -21.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.52% during the next five years compared to 36.92% growth over the previous five years of trading.

Atossa Therapeutics Inc (NASDAQ: ATOS) Trading Performance Indicators

Atossa Therapeutics Inc (ATOS) is currently performing well based on its current performance indicators. A quick ratio of 12.67 was reported for the most recent quarter.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.21, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.27 in one year’s time.

Technical Analysis of Atossa Therapeutics Inc (ATOS)

Looking closely at Atossa Therapeutics Inc (NASDAQ: ATOS), its last 5-days average volume was 0.75 million, which is a jump from its year-to-date volume of 0.69 million. As of the previous 9 days, the stock’s Stochastic %D was 24.53%. Additionally, its Average True Range was 0.07.

During the past 100 days, Atossa Therapeutics Inc’s (ATOS) raw stochastic average was set at 60.73%, which indicates a significant increase from 40.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 99.94% in the past 14 days, which was higher than the 73.09% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $0.7647, while its 200-day Moving Average is $1.0567. However, in the short run, Atossa Therapeutics Inc’s stock first resistance to watch stands at $0.9179. Second resistance stands at $0.9689. The third major resistance level sits at $1.0379. If the price goes on to break the first support level at $0.7979, it is likely to go to the next support level at $0.7289. Should the price break the second support level, the third support level stands at $0.6779.

Atossa Therapeutics Inc (NASDAQ: ATOS) Key Stats

Market capitalization of the company is 111.96 million based on 129,170K outstanding shares. Right now, sales total 0 K and income totals -25,500 K. The company made 0 K in profit during its latest quarter, and -6,720 K in sales during its previous quarter.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.